AFLOQUALONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H14FN3O
Molecular Weight	283.3003
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(C=CC=C1)N2C(=O)C3=CC(N)=CC=C3N=C2CF

InChI

InChIKey=VDOSWXIDETXFET-UHFFFAOYSA-N

InChI=1S/C16H14FN3O/c1-10-4-2-3-5-14(10)20-15(9-17)19-13-7-6-11(18)8-12(13)16(20)21/h2-8H,9,18H2,1H3

HIDE SMILES / InChI

Molecular Formula	C16H14FN3O
Molecular Weight	283.3003
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7109348
Curator's Comment: Description was created based on several sources, including https://www.researchgate.net/publication/235333319_Quinazoline_Marketed_drugs_-_A_Review

Afloqualone (AFQ) is one of the centrally acting muscle relaxants. It is a quinazolinone family GABAergic drug and is an analogue of methaqualone developed in the 1970s by a team at Tanabe Seiyaku. It has sedative and muscle-relaxant effects resulting from its agonist activity at the β subtype of the GABAa receptor, and has had some clinical use, although it causes photosensitization as a side-effect that can cause skin problems such as dermatitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA receptor alpha, Beta subtype, Felis catus 1 Target ID: GABA receptor alpha, Beta subtype, Felis catus Sources: http://www.ncbi.nlm.nih.gov/pubmed/7109348	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Muscle hypertonia 3 Sources: http://www.ndrugs.com/?s=arofuto	Primary		Approved 8429	Arofuto Approved Use Indications: muscle hypertonia, spastic paralysis
Spastic paralysis 3 Sources: http://www.ndrugs.com/?s=arofuto	Primary		Approved 8429	Arofuto Approved Use Indications: muscle hypertonia, spastic paralysis

PubMed

Title	Date	PubMed
Characterization of afloqualone N-glucuronidation: species differences and identification of human UDP-glucuronosyltransferase isoform(s).	2005 Jan	15475412
Determination of afloqualone in human plasma using liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic studies in humans.	2007 Oct 15	19073082
Evaluation of photoallergic potential of chemicals using THP-1 cells.	2008 Nov	18693085
Comparison between open procedure and tubular retractor assisted procedure for cervical radiculopathy: results of a randomized controlled study.	2009 Aug	19654947
Induction of eosinophil-infiltrating drug photoallergy in mice.	2009 Jul	19329284
Exodeviated ophthalmoplegia in a patient with progressive supranuclear palsy.	2009 Oct	19795006
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

Afloqualonen (40 mg) was orally administered

Route of Administration: Oral

In Vitro Use Guide

Afloqualone inhibited spontaneous movements of isolated rabbit atrium and ileum and isolated rat uterus at considerably high concentrations of 10(-6) g/ml or more.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:28:34 UTC 2023` Edited by `admin` on `Sat Dec 16 17:28:34 UTC 2023`
Record UNII	CO4U2C8ORZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AFLOQUALONE

Official Name

English

Afloqualone [WHO-DD]

Common Name

English

AIROMATE

Brand Name

English

AFLOQUALONE [JAN]

Common Name

English

AFLOQUALONE [MI]

Common Name

English

AFLOQUALONE [MART.]

Common Name

English

afloqualone [INN]

Common Name

English

6-AMINO-2-(FLUOROMETHYL)-3-O-TOLYL-4(3H)-QUINAZOLINONE

Common Name

English

Classification Tree Code System Code

WIKIPEDIA

Designer-drugs-Afloqualone